Market Closed -
London S.E.
15:40:39 27/10/2023 BST
|
5-day change
|
1st Jan Change
|
41.75
USD
|
-21.08%
|
|
-14.14%
|
-15.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
112,310
|
98,877
|
111,194
|
112,665
|
112,549
|
113,686
|
-
|
-
|
Enterprise Value (EV)
1 |
128,816
|
107,666
|
121,177
|
119,102
|
120,342
|
120,646
|
116,213
|
111,707
|
P/E ratio
|
40
x
|
8.01
x
|
17.8
x
|
16.7
x
|
20.8
x
|
16.4
x
|
13.3
x
|
11.9
x
|
Yield
|
3.51%
|
4.07%
|
3.76%
|
3.96%
|
4.19%
|
4.25%
|
4.48%
|
4.9%
|
Capitalization / Revenue
|
3.11
x
|
2.74
x
|
2.94
x
|
2.62
x
|
2.61
x
|
2.45
x
|
2.29
x
|
2.16
x
|
EV / Revenue
|
3.57
x
|
2.99
x
|
3.21
x
|
2.77
x
|
2.79
x
|
2.6
x
|
2.34
x
|
2.12
x
|
EV / EBITDA
|
10.8
x
|
9.41
x
|
9.95
x
|
8.14
x
|
8.44
x
|
8.9
x
|
7.52
x
|
6.76
x
|
EV / FCF
|
21.7
x
|
15.4
x
|
15
x
|
14
x
|
14.2
x
|
16.5
x
|
12.8
x
|
11.1
x
|
FCF Yield
|
4.6%
|
6.48%
|
6.68%
|
7.12%
|
7.04%
|
6.05%
|
7.83%
|
9.03%
|
Price to Book
|
1.9
x
|
1.57
x
|
1.62
x
|
1.5
x
|
1.52
x
|
1.47
x
|
1.39
x
|
1.31
x
|
Nbr of stocks (in thousands)
|
1,253,178
|
1,256,375
|
1,255,293
|
1,254,060
|
1,253,891
|
1,250,117
|
-
|
-
|
Reference price
2 |
89.62
|
78.70
|
88.58
|
89.84
|
89.76
|
90.94
|
90.94
|
90.94
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
01/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
36,126
|
36,041
|
37,761
|
42,997
|
43,070
|
46,325
|
49,752
|
52,646
|
EBITDA
1 |
11,904
|
11,443
|
12,183
|
14,627
|
14,259
|
13,556
|
15,462
|
16,523
|
EBIT
1 |
9,758
|
9,762
|
10,714
|
13,040
|
12,670
|
12,144
|
13,782
|
14,916
|
Operating Margin
|
27.01%
|
27.09%
|
28.37%
|
30.33%
|
29.42%
|
26.21%
|
27.7%
|
28.33%
|
Earnings before Tax (EBT)
1 |
2,822
|
13,804
|
7,798
|
8,268
|
7,038
|
8,912
|
11,520
|
13,015
|
Net income
1 |
2,806
|
12,314
|
6,223
|
6,720
|
5,400
|
7,066
|
8,574
|
9,531
|
Net margin
|
7.77%
|
34.17%
|
16.48%
|
15.63%
|
12.54%
|
15.25%
|
17.23%
|
18.1%
|
EPS
2 |
2.240
|
9.820
|
4.970
|
5.370
|
4.310
|
5.549
|
6.819
|
7.669
|
Free Cash Flow
1 |
5,928
|
6,982
|
8,096
|
8,483
|
8,478
|
7,297
|
9,096
|
10,083
|
FCF margin
|
16.41%
|
19.37%
|
21.44%
|
19.73%
|
19.68%
|
15.75%
|
18.28%
|
19.15%
|
FCF Conversion (EBITDA)
|
49.8%
|
61.02%
|
66.45%
|
58%
|
59.46%
|
53.83%
|
58.83%
|
61.03%
|
FCF Conversion (Net income)
|
211.26%
|
56.7%
|
130.1%
|
126.24%
|
157%
|
103.27%
|
106.09%
|
105.8%
|
Dividend per Share
2 |
3.150
|
3.200
|
3.330
|
3.560
|
3.760
|
3.869
|
4.070
|
4.457
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
01/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
10,432
|
9,994
|
9,674
|
10,116
|
12,482
|
10,725
|
10,222
|
9,965
|
11,964
|
10,919
|
10,464
|
10,413
|
12,974
|
11,878
|
10,805
|
EBITDA
1 |
3,952
|
2,623
|
3,426
|
3,163
|
4,931
|
3,107
|
3,703
|
3,087
|
4,460
|
3,009
|
3,192
|
2,706
|
4,328
|
2,628
|
-
|
EBIT
1 |
3,558
|
2,256
|
3,065
|
2,753
|
4,498
|
2,724
|
3,333
|
2,726
|
4,028
|
2,583
|
2,843
|
2,614
|
4,185
|
2,787
|
3,045
|
Operating Margin
|
34.11%
|
22.57%
|
31.68%
|
27.21%
|
36.04%
|
25.4%
|
32.61%
|
27.36%
|
33.67%
|
23.66%
|
27.17%
|
25.11%
|
32.26%
|
23.47%
|
28.18%
|
Earnings before Tax (EBT)
1 |
2,957
|
1,391
|
2,349
|
1,383
|
2,666
|
1,921
|
2,468
|
1,718
|
2,971
|
-249
|
1,310
|
2,011
|
3,684
|
2,137
|
-
|
Net income
1 |
2,317
|
1,131
|
2,009
|
1,175
|
2,076
|
1,460
|
1,995
|
1,435
|
2,525
|
-555
|
1,133
|
1,509
|
2,797
|
1,614
|
-
|
Net margin
|
22.21%
|
11.32%
|
20.77%
|
11.62%
|
16.63%
|
13.61%
|
19.52%
|
14.4%
|
21.1%
|
-5.08%
|
10.83%
|
14.49%
|
21.56%
|
13.59%
|
-
|
EPS
2 |
1.850
|
0.9000
|
1.610
|
0.9400
|
1.660
|
1.160
|
1.600
|
1.150
|
2.010
|
-0.4400
|
0.9100
|
1.201
|
2.219
|
1.280
|
-
|
Dividend per Share
2 |
-
|
3.330
|
-
|
-
|
-
|
3.560
|
-
|
-
|
-
|
3.760
|
0.9292
|
0.9289
|
0.9289
|
0.9289
|
0.9885
|
Announcement Date
|
28/10/21
|
04/02/22
|
28/04/22
|
28/07/22
|
28/10/22
|
03/02/23
|
27/04/23
|
28/07/23
|
27/10/23
|
01/02/24
|
25/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
16,506
|
8,789
|
9,983
|
6,437
|
7,793
|
6,961
|
2,528
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,978
|
Leverage (Debt/EBITDA)
|
1.387
x
|
0.7681
x
|
0.8194
x
|
0.4401
x
|
0.5465
x
|
0.5135
x
|
0.1635
x
|
-
|
Free Cash Flow
1 |
5,928
|
6,982
|
8,096
|
8,483
|
8,478
|
7,297
|
9,096
|
10,083
|
ROE (net income / shareholders' equity)
|
12.7%
|
12.1%
|
12.5%
|
14.4%
|
13.6%
|
12.3%
|
13.5%
|
13.9%
|
ROA (Net income/ Total Assets)
|
2.5%
|
6.47%
|
5.3%
|
8.37%
|
4.27%
|
6.36%
|
7.22%
|
7.45%
|
Assets
1 |
112,072
|
190,442
|
117,327
|
80,248
|
126,517
|
111,039
|
118,735
|
127,854
|
Book Value Per Share
2 |
47.20
|
50.30
|
54.80
|
59.70
|
59.20
|
61.70
|
65.30
|
69.20
|
Cash Flow per Share
2 |
6.160
|
5.940
|
8.360
|
8.410
|
8.200
|
8.070
|
9.460
|
10.90
|
Capex
1 |
1,816
|
1,329
|
2,043
|
2,201
|
3,024
|
1,987
|
2,397
|
2,501
|
Capex / Sales
|
5.03%
|
3.69%
|
5.41%
|
5.12%
|
7.02%
|
4.29%
|
4.82%
|
4.75%
|
Announcement Date
|
06/02/20
|
05/02/21
|
04/02/22
|
03/02/23
|
01/02/24
|
-
|
-
|
-
|
Last Close Price
90.94
EUR Average target price
108.1
EUR Spread / Average Target +18.86% Consensus |
1st Jan change
|
Capi.
|
---|
| +56.89% | 823B | | +39.52% | 627B | | -6.55% | 353B | | +15.99% | 320B | | +7.92% | 295B | | +13.74% | 239B | | +13.83% | 220B | | -0.49% | 219B | | +7.94% | 167B |
Other Pharmaceuticals
|